Novartis Gene Therapies, Inc.
Date updated: 2026-04-19
TOTAL PRODUCT APPROVED: 1
Overview
Product Registered
Categories
Type of Products
Analysis
Product Holder
| Product holder name | Product count |
|---|---|
| 1 |
Product count1
Rows per page:
1–1 of 1
Analysis
Product API
| Ingredient (API) name | Product count |
|---|---|
| 1 |
Product count1
Rows per page:
1–1 of 1
Related Articles
The Future of Community Pharmacy: A Shift from Products to Patients Centric Care
Manfye Goh · 11 min read
Bridging the Gap: Assessing Hypertension Drug Availability and Alignment with Malaysian CPG Guidelines and MOH Formulary
Manfye Goh · 12 min read
4 Rising M’sian Pharmacy-Tech Startups to Watch in 2022
Jiaying Cheang · 7 min read
Listing
Registered Product
| Product name | Product Reg. no | Type | Product Holder | Manufacturer | Importer | Registration Status |
|---|---|---|---|---|---|---|
| Zolgensma 2 x 10^13 vg/mL Suspension for Intravenous Infusion | MAL24026006AZ | BIOLOGICS | NOVARTIS CORPORATION (MALAYSIA) SDN. BHD. | Novartis Gene Therapies, Inc. | NOVARTIS CORPORATION (MALAYSIA) SDN. BHD. | PRODUCT APPROVED |
Zolgensma 2 x 10^13 vg/mL Suspension for Intravenous Infusion
Product Reg. noMAL24026006AZ
TypeBIOLOGICS
Product HolderNOVARTIS CORPORATION (MALAYSIA) SDN. BHD.
ManufacturerNovartis Gene Therapies, Inc.
ImporterNOVARTIS CORPORATION (MALAYSIA) SDN. BHD.
Registration StatusPRODUCT APPROVED
Rows per page:
1–1 of 1